Scoble, Patrick J.
Reilly, Joseph
Tillotson, Glenn S.
Article History
First Online: 25 June 2020
Compliance with Ethical Standards
:
: No funding was received for the preparation of this manuscript. This article is part of a supplement wholly funded by Melinta Therapeutics.
: P.J.S. serves as a consultant for Iterum Pharmaceuticals LTD, Shionogi & Co., LTD, and Spero Therapeutics. JR receives speaker fees from Melinta Therapeutics. GST serves as consultant to Melinta Therapeutcs, Shionogi Inc, Summit plc, KBP Biosciences and Aim Max Therapeutics.